

freedom.information@wvt.nhs.uk

22 July 2020

FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST FOI2020/0048

Thank you for your request for information.

Wye Valley NHS Trust responds:

//////////REQUEST

I have a Freedom of Information request regarding Ophthalmology. Could you kindly provide the answers to the questions mentioned below?

1. Within your trust how many **intra-vitre al injections/implants** of each of the following drugs have been used in the four-month period from January to April 2020:

| | |
|----------------|--------------|
| Abicipar pegol | 0 |
| Aflibercept | 267 |
| Bevacizumab | 39 |
| Brolucizumab | 0 |
| Dexamethasone | 18 |
| Fluocinolone | Less than 6* |
| Ranibizumab | 591 |

***This relates to a low number. Under section 40ii of the Freedom of Information Act 2000 information that can potentially identify individual data (as defined by the Data Protection Act 2018) cannot be shared. This includes statistically low information.**

2. If your trust is able to identify **intra-vitre al injections/implants** by eye condition, please provide the number of injections/implants used from January to April 2020, for each of the following conditions:

The Trust is not able to identify **intra-vitre al injections/implants** by eye condition due to the way data is currently recorded.

Wet Age Related Macular Degeneration (wAMD)

Abicipar pegol
Aflibercept
Bevacizumab
Brolucizumab
Dexamethasone
Fluocinolone
Ranibizumab

Diabetic Macular Oedema (DMO)

Abicipar pegol

Aflibercept

Bevacizumab

Brolucizumab

Dexamethasone

Fluocinolone

Ranibizumab

Retinal Vein Occlusion - Central (CRVO)

Abicipar pegol

Aflibercept

Bevacizumab

Brolucizumab

Dexamethasone

Fluocinolone

Ranibizumab

Retinal Vein Occlusion - Branch (BRVO)

Abicipar pegol

Aflibercept

Bevacizumab

Brolucizumab

Dexamethasone

Fluocinolone

Ranibizumab

Visual impairment due to choroidal neovascularization secondary to pathologic myopia (mCNV)

Abicipar pegol

Aflibercept

Bevacizumab

Brolucizumab

Dexamethasone

Fluocinolone

Ranibizumab

Please note that a record of previous Trust FOI responses is now available to consult online by visiting:

<https://www.wyevalley.nhs.uk/about-us/information-requests/freedom-of-information-requests.aspx>

If you have queries or any concerns contact details are given at the top of the letter. Please remember to quote the reference number above in any future communications.

If you are unhappy with the service you have received in relation to your request and wish to make a complaint or request a review of our decision, you should write to:

Information Governance/Privacy Officer

Wye Valley NHS Trust

Monkmoor Court

31-34 Commercial Road

Hereford

HR1 2DX

Email: freedom.information@wt.nhs.uk

If you are not content with the outcome of your complaint, you may apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted at:

Information Commissioner's Office
Wycliffe House,
Water Lane,
Wilmslow,
Cheshire, SK9 5AF

Telephone: 0303 123 1113 www.ico.gov.uk

Yours sincerely,

Freedom of Information Coordinator

Re-Use of Public Sector Information

All information supplied by the Trust in answering a request for information (RFI) under the Freedom of Information Act 2000 will be subject to the terms of the Re-use of Public Sector Information Regulations 2005, Statutory Instrument 2005 No. 1515 which came into effect on 1st July 2005.

Under the terms of the Regulations, the Trust will licence the re-use of any or all information supplied if being used in a form and for the purpose other than which it was originally supplied. This license for re-use will be in line with the requirements of the Regulations and the licensing terms and fees as laid down by the Office of Public Sector Information (OPSI). Most licenses will be free; however the Trust reserves the right, in certain circumstances, to charge a fee for the re-use of some information which it deems to be of commercial value. Further information can be found at www.opsi.gov.uk where a sample license terms and fees can be found with guidance on copyright and publishing notes and a Guide to Best Practice and regulated advice and case studies, at www.opsi.gov.uk/advice/psi-regulations/index.htm